IGF-1 therapy will lead donohue syndrome treatment sales through 2036 with 61.3% of the treatment segment in 2026. The market was valued at USD 18.39 billion in 2025 and is expected to be worth USD 26.84 billion by 2036, creating an incremental opportunity of USD 7.81 billion worldwide.